Evotec SE (EVO)
EVO Stock Price Chart
Explore Evotec SE interactive price chart. Choose custom timeframes to analyze EVO price movements and trends.
EVO Company Profile
Discover essential business fundamentals and corporate details for Evotec SE (EVO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
5 Feb 2004
Employees
4.77k
Website
https://www.evotec.comCEO
Christian Wojczewski
Description
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
EVO Financial Timeline
Browse a chronological timeline of Evotec SE corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.05, while revenue estimate is $201.32m.
Earnings released on 6 May 2026
EPS came in at -$0.46 falling short of the estimated -$0.15 by -209.49%, while revenue for the quarter reached $213.62m , beating expectations by +4.52%.
Earnings released on 8 Apr 2026
EPS came in at $0.05 falling short of the estimated $0.21 by -73.96%, while revenue for the quarter reached $347.64m , beating expectations by +5.74%.
Earnings released on 5 Nov 2025
EPS came in at -$0.14 falling short of the estimated -$0.14 by -1.44%, while revenue for the quarter reached $191.95m , missing expectations by -19.99%.
Earnings released on 13 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.18 by +19.93%, while revenue for the quarter reached $201.62m , beating expectations by +5.12%.
Earnings released on 6 May 2025
EPS came in at -$0.19 falling short of the estimated -$0.11 by -77.26%, while revenue for the quarter reached $219.23m , missing expectations by -20.54%.
Earnings released on 17 Apr 2025
EPS came in at -$0.12 falling short of the estimated $0.02 by -768.15%, while revenue for the quarter reached $229.08m , beating expectations by +11.58%.
Earnings released on 6 Nov 2024
EPS came in at -$0.12 falling short of the estimated -$0.08 by -50.00%, while revenue for the quarter reached $202.77m , missing expectations by -8.28%.
Earnings released on 14 Aug 2024
EPS came in at -$0.29 falling short of the estimated -$0.09 by -222.22%, while revenue for the quarter reached $195.83m , missing expectations by -11.58%.
Earnings released on 22 May 2024
EPS came in at -$0.05 falling short of the estimated -$0.03 by -49.52%, while revenue for the quarter reached $224.23m , missing expectations by -0.04%.
Earnings released on 26 Feb 2024
EPS came in at -$0.05 falling short of the estimated -$0.03 by -66.67%, while revenue for the quarter reached $221.40m .
Earnings released on 8 Nov 2023
EPS came in at -$0.12 falling short of the estimated -$0.05 by -140.00%, while revenue for the quarter reached $207.04m , beating expectations by +1.46%.
Earnings released on 29 Aug 2023
EPS came in at -$0.04 falling short of the estimated -$0.04 by -10.93%, while revenue for the quarter reached $185.76m , missing expectations by -13.54%.
Earnings released on 12 May 2023
EPS came in at -$0.08 falling short of the estimated $0.10 by -180.00%, while revenue for the quarter reached $232.18m .
Earnings released on 29 Mar 2023
EPS came in at -$0.13 falling short of the estimated $0.10 by -230.00%, while revenue for the quarter reached $259.26m , beating expectations by +9.63%.
Earnings released on 9 Nov 2022
EPS came in at -$0.26 falling short of the estimated $0.08 by -419.52%, while revenue for the quarter reached $169.81m , missing expectations by -6.89%.
Earnings released on 11 Aug 2022
EPS came in at -$0.08 falling short of the estimated -$0.02 by -375.06%, while revenue for the quarter reached $180.13m , beating expectations by +1.40%.
Earnings released on 11 May 2022
EPS came in at -$0.23 falling short of the estimated $0.06 by -483.33%, while revenue for the quarter reached $182.15m , beating expectations by +6.40%.
Earnings released on 12 Apr 2022
EPS came in at -$0.11 falling short of the estimated $0.07 by -257.14%, while revenue for the quarter reached $212.08m , beating expectations by +13.15%.
Earnings released on 11 Nov 2021
EPS came in at $0.95 , while revenue for the quarter reached $185.32m , missing expectations by -11.64%.
Stock split effective on 20 Oct 2021
Shares were split 4 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2021
EPS came in at $0.43 , while revenue for the quarter reached $163.99m .
EVO Stock Performance
Access detailed EVO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
